Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration

被引：1
|
作者：
Shao, Y-Y. [1 ]
Chen, B-B. [2 ]
Lin, Z-Z. [3 ]
Hsu, C-H. [1 ]
Wang, M-J. [3 ]
Cheng, A-L. [1 ]
Hsu, C. [1 ]
机构：
[1] Natl Taiwan Univ NTU, Grad Inst Oncol, Coll Med, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Radiol, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw371.99
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
707P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Targeted agents for second-line treatment of advanced hepatocellular carcinoma
    Personeni, Nicola
    Pressiani, Tiziana
    Bozzarelli, Silvia
    Rimassa, Lorenza
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2019, 11 (10) : 788 - 803
  • [22] Targeted agents for second-line treatment of advanced hepatocellular carcinoma
    Nicola Personeni
    Tiziana Pressiani
    Silvia Bozzarelli
    Lorenza Rimassa
    World Journal of Gastrointestinal Oncology, 2019, (10) : 788 - 803
  • [23] Pembrolizumab as second-line therapy for advanced urothelial carcinoma
    Douchet, G.
    ONCOLOGIE, 2017, 19 (5-6) : 205 - 206
  • [24] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    Bellmunt, J.
    de Wit, R.
    Vaughn, D. J.
    Fradet, Y.
    Lee, J. -L.
    Fong, L.
    Vogelzang, N. J.
    Climent, M. A.
    Petrylak, D. P.
    Choueiri, T. K.
    Necchi, A.
    Gerritsen, W.
    Gurney, H.
    Quinn, D. I.
    Culine, S.
    Sternberg, C. N.
    Mai, Y.
    Poehlein, C. H.
    Perini, R. F.
    Bajorin, D. F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11): : 1015 - 1026
  • [25] The survival and safety of metastatic hepatocellular carcinoma treated with lenalidomide as second-line therapy: a case report and review of the literature
    Li, Tao
    Zhao, Ying
    Li, Keren
    Li, Gong
    Li, Guangxin
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [26] Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
    Trojan, Joerg
    Waidmann, Oliver
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2016, 3 : 31 - 36
  • [27] Eligibility for Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma A Population-based Study
    Tsang, Erica S.
    Davies, Janine M.
    Loree, Jonathan M.
    Lim, Howard J.
    Renouf, Daniel J.
    Gill, Sharlene
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (11): : 788 - 791
  • [28] Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma
    Rimassa, Lorenza
    Woerns, Marcus-Alexander
    LIVER INTERNATIONAL, 2020, 40 (08) : 1800 - 1811
  • [29] Bevacizumab (BVZ) as second-line treatment after sorafenib (SFB) progression in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Pazo Cid, R. A.
    Esquerdo, G.
    Puertolas, T.
    Calderero, V.
    Gil, I.
    Lao, J.
    Millastre, E.
    Alvarez-Alejandro, M.
    Madani, J.
    Anton, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
    Chiang, Chi-leung
    Chan, Sik-kwan
    Lee, Shing-fung
    Wong, Irene Oi-ling
    Choi, Horace Cheuk-wai
    JAMA NETWORK OPEN, 2021, 4 (01)
12345